Oral drug delivery as an alternative to needle-based injection for large molecules : an assessment of the field & evaluation of high-priority technologies

Oral delivery of large molecules is widely considered the "holy grail" of drug delivery, but attempts to achieve this within the past century have been met with a lack of success, confounded by low bioavailability. Novel mechanisms need to be assessed in order to deliver a clinically relevant amount of drug into systemic circulation, while protecting the drug from pH denaturation and the harsh enzymatic environment of the gut. To assess the field, this thesis evaluates startup companies and academic labs focusing their efforts on the oral delivery of biologics. The holistic, phased analysis of the field includes the following items: ** Value proposition assessment as applicable to Amgen's pipeline; ** Literature review into historical barriers; ** Technology landscape of the current space; ** Down-selection to highly valued technology prospects; ** Risk assessment and mitigation planning activities.

Name thesis:degree_name

Master

Department dc:contributor.department

Sloan School of Management

Grantor dc:publisher

Massachusetts Institute of Technology

Year dc:date.issued

2018

Author dc:creator

• Nealon, Kaitlyn Louise.

Advisor dc:contributor.advisor

• Roger Kamm and Thomas Roemer.

• Sloan School of Management.
• Mechanical Engineering.
• Leaders for Global Operations Program.

Statement dc:rights

• MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission.

Licence dc:rights.uri

• http://dspace.mit.edu/handle/1721.1/7582

Language dc:language.iso

eng

Handle dc:identifier.uri

https://hdl.handle.net/1721.1/122838

OAI identifier oai:identifier

oai:dspace.mit.edu:1721.1/122838